Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma
Abstract
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Drugs that induce targeted protein degradation, such as thalidomide analogues, have a number of unique pharmacological features in comparison with conventional enzyme inhibitors.
“Drugs that induce targeted protein degradation, such as thalidomide analogues, have a number of unique pharmacological features in comparison with conventional enzyme inhibitors58,138–140.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [138]
Cites
SCORTEN: A Severity-of-Illness Score for Toxic Epidermal Necrolysis
Fouchard, N., Bertocchi, M., Roujeau, J., Revuz, J. E., Wolkenstein, P., & Bastuji‐Garin, S. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00061.x · Cited by 1,213 · see citing works
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147 · see citing works
Self-citationRajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70284-0 · Cited by 933 · see citing works
Richardson, P. G. G., Jagannath, S., Hussein, M. A., Berenson, J. R., Singhal, S., Irwin, D. H., WILLIAMS, S. F., Bensinger, W., Badros, A. Z., Vescio, R. A., et al. (2009) · Blood · doi:10.1182/blood-2008-12-196238 · Cited by 158 · see citing works
Self-citationDermatologic Adverse Effects of Lenalidomide Therapy for Amyloidosis and Multiple Myeloma
Sviggum, H. P., Davis, M. D. P., Rajkumar, S. V., et al. (2006) · Archives of Dermatology · doi:10.1001/archderm.142.10.1298 · Cited by 93 · see citing works
Nardone, B., Wu, S., Garden, B. C., West, D. P., Reich, L. M., & Lacouture, M. E. (2013) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2013.03.006 · Cited by 44 · see citing works
Desensitization to Lenalidomide in a Patient With Relapsed Multiple Myeloma
Seki, J. T., Banglawala, S., Lentz, E. M., et al. (2012) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2012.09.003 · Cited by 18 · see citing works
Successful desensitization in a patient with lenalidomide hypersensitivity
Phillips, J., Kujawa, J., Davis-Lorton, M. A., et al. (2007) · American Journal of Hematology · doi:10.1002/ajh.21004 · Cited by 16 · see citing works
Penna, G., Allegra, A., Romeo, G., et al. (2011) · Acta Oncologica · doi:10.3109/0284186x.2011.640347 · Cited by 13 · see citing works
[Desensitization to lenalidomide].
Orbis, I. C., Muñoz, C. G., Cascajares, S. C., et al. (2014) · PubMed · doi:10.7399/fh.2012.36.6.46 · Cited by 4 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137 · see citing works
- Authors
- Lee, M. J., Wickner, P., Fanning, L., Schlossman, R., Richardson, P., Laubach, J., & Castells, M.
- Affiliations
- Brigham and Women's Hospital (US)
- Dana-Farber Cancer Institute (US)
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2014-05-14
- Volume
- 167
- Issue
- 1
- Pages
- 127-131
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2065974097
- Cited by
- 31
- References
- 10
- Citations by year
- 2026: 2 · 2025: 2 · 2023: 2 · 2022: 6 · 2021: 4 · 2020: 2 · 2019: 5 · 2018: 2 · 2017: 3 · 2016: 1 · 2015: 1 · 2014: 1
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- British Journal of Haematology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Pharmacology › Drug-Induced Adverse Reactions
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Keywords
- lenalidomide, drug desensitization, delayed-type hypersensitivity, multiple myeloma, drug hypersensitivity, adverse drug reaction management
- MeSH terms
- Lenalidomide, Desensitization, Immunologic, Drug Hypersensitivity, Female, Humans, Hypersensitivity, Delayed, Immunologic Factors, Male, Middle Aged, Multiple Myeloma, Thalidomide, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
